New drug for moderate to severe lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 or older (18 in China).
- You must have been diagnosed with lupus (SLE) for at least 6 months.
- Your lupus must be moderate or severe, with current symptoms in at least 2 organ systems or one severe symptom.
- You must have lab evidence of lupus activity, like certain antibodies or low complement levels.
- You must be on a stable dose of standard lupus medications (such as antimalarials, steroids, or immunosuppressants).
- You cannot have serious infections, recent live vaccines, or certain cancers in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.